Navigation Links
Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
Date:5/16/2008

REINACH, Switzerland, May 16 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for intravenous iclaprim in the treatment of complicated Skin and Skin Structure Infections (cSSSI). Arpida completed the submission of the NDA to the agency in March 2008. FDA has assigned a standard ten month review to the iclaprim NDA and has established the Prescription Drug User Fee Act (PDUFA) action date for the NDA to be 16 January 2009.

Dr Jurgen Raths, CEO of Arpida Ltd. commented: "We are very pleased with the FDA's acceptance of our NDA. This marks another step towards our goal of launching iclaprim and providing a promising treatment option for patients suffering from serious or life-threatening infections. We look forward to continue to work with the US authorities to facilitate their review of the NDA. In the meantime, work on the European filing is progressing and we expect to submit the Marketing Authorisation Application in the EU around the middle of this year. Furthermore, we will increasingly focus on the build-up of a commercial structure."

The iclaprim NDA contains data from 15 clinical studies, including two well-controlled multinational pivotal Phase III trials (ASSIST-1 and ASSIST-2, in which approximately 1,000 patients were enrolled and treated). Patients enrolled in both Phase III trials exhibited high incidences of methicillin-resistant Staphylococcus aureus (MRSA). In these studies, iclaprim showed high clinical and microbiological cure rates and was well-tolerated with a safety profile which was compatible with treatment of patients with cSSSI.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The mo
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ire-FirstCall/ -- Isis Pharmaceuticals,Inc. (Nas... , What: New findings published in the jour... known as miR-21, in heart failure, When: ....m. PT, Where: http://www.isispharm.com ,...o our website listed above., , If you ar...
(Date:12/1/2008)...Call/ -- Cell Therapeutics, Inc. (CTI),(Nasdaq an...d Drug,Administration (FDA) has accepted for fili...atus for, the supplemental Biologics License Appli...momab tiuxetan) as consolidation,therapy for pati... who achieve,a response to first-line therapy. Pr...
(Date:11/28/2008)...rstCall/ -- ExonHit Therapeutics S.A.,(Alternext:...announces today,the availability of its new Splic...man disease. These SpliceArray(TM) products help o...c target discovery and validation efforts. Using,... we identify novel,transcripts coding for new pro...
(Date:11/27/2008)...tCall/ -- On Monday, December 1, 2008, at,8:30 a....cific, members of,Cell Therapeutics, Inc.,s (CTI)... a conference call to discuss the agreement with S...jointly market and develop Zevalin(R). , , ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:...
Breaking Biology Technology:FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 2ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies 3
...00 million to develop torcetrapib, a heart drug th... die in clinical trials. Hours after learning the ... halt to further trials, a decision that sent its ...dy. , ,The drama surrounding Pfizer,s high-stakes ...pharmaceutical industry, but it also exposes the c...
...ers polled in a recent survey say that concerns ab...es outweigh anxiety about offshore competition. , ...p , a nonprofit consulting organization for small ...of 173 Wisconsin firms. They ranked themselves on ...mately one-third of respondents reported growing s...
...son-based company engaged in gene therapy and the ...ed States patent on a new injection delivery metho...lack of an effective method to deliver nucleic aci... along with collaborators at the University of Wi...thod of injection. , ,RNA interference is a cellu...
...ree-part series of op-ed pieces on corporate gover... Perspectives column, are written by associates in... Solutions, LLC . , ,According to the Associatio...percent of frauds are detected by someone saying s... percent; and internal controls, 19.2 percent). If...
Other Biology Technology:Failure of heart drug offers lessons for drug industry 2Failure of heart drug offers lessons for drug industry 3Mirus Bio awarded patent on RNA delivery 2Mirus Bio awarded patent on RNA delivery 3I can tell you - you're my lawyer, right? 2I can tell you - you're my lawyer, right? 3I can tell you - you're my lawyer, right? 4I can tell you - you're my lawyer, right? 5I can tell you - you're my lawyer, right? 6
(Date:12/1/2008)...ea and land animals around a group of Antarctic is...y and has more species than the Galapagos. The stu...they will respond to future environmental change. ...raphy , the team from British Antarctic Survey and...he land, sea and shores of the South Orkney Island...
(Date:12/1/2008)...rmission has been granted to start the first safet...for ALS. ALS is an incurable, paralyzing neurodege...100,000. The disease commonly affects healthy peop...; without warning. Researchers from VIB at the K.U...r the use of VEGF in the treatment of ALS through ...
(Date:12/1/2008)...y a crucial role in the global carbon cycle that h...ogist Dr. Tom Battin, of the University of Vienna,...n October that our understanding of how rivers and...cally. , Microorganisms such as bacteria and sin...rganic matter as it flows downstream. They convert...
(Date:12/1/2008)...en presented with a chemoattractant signal like cA...ized morphology and aggregate to form a migrating ...program that culminates in the formation of a mult...treaming response is coordinated at a single-cell ...l of Cell Biology ( www.jcb.org ). , Besides ac...
Breaking Biology News(10 mins):First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3Rivers are carbon processors, not inert pipelines 2YogaPro Celebrates Mothers Day with a Photo Contest to Win YogaToes 28R 29 Foot Care Exercisers to Soothe and Beautify Moms Feet 15010 1YogaPro Celebrates Mothers Day with a Photo Contest to Win YogaToes 28R 29 Foot Care Exercisers to Soothe and Beautify Moms Feet 15010 2MRI 3A A window to genetic properties of brain tumors 15007 1MRI 3A A window to genetic properties of brain tumors 15007 2Hologic to Present at the Bank Of America 2008 Smid Cap Conference 15004 1Hologic to Present at the Bank Of America 2008 Smid Cap Conference 15004 2Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 1Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 2Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 3Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 4Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 5Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 6Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 7Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 8Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 9Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 10Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 11Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 12Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 13Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31 2007 15001 14
...ysics to show how our circadian clocks manage to k...t. , In an article appearing March 13 in the jour...e Ecole Polytechnique Federale de Lausanne demonst...pends on specific biochemical processes, reflectin...by advanced sleep phase syndrome. , Circadian r...
...ide researchers with a more reliable method of dia... Purdue University researchers bound a complex nan...tification tag that was delivered to specific prot... scientists want to find a better way to ascertain...ins involved in disease processes. They also hope ...
...etic traits that influence social interactions amo...ck. , Scientists from Purdue University, the Neth...s based on traits to choose animals that are more ...epartment of Animal Sciences geneticist. The new m... well-being and to securing the world,s future foo...
...h fellow at the San Francisco VA Medical Center an... one of only three scientists named in January 200...l Space Biomedical Research Institute (NSBRI). , L...ses and possible methods of treating or preventing...ness of space travel. , The research also has ...
Other Biology News:Keeping the body in sync -- The stability of cellular clocks 2Scientists use nanoparticle to discover disease-causing proteins 2Scientists find method to pick noncompetitive animals, improve production 2Researcher to study astronaut bone loss for space biology agency 2Researcher to study astronaut bone loss for space biology agency 3
Human GATA-2 Affinity Purified Polyclonal Ab
...s the lowest priced, full ring small animal imagin...4 low retail price, it outperfoms every competing ...performance, energy resolution, timing resolution,... animal PET (Positron Emission Tomography) imaging...
REC. PROTEIN G from Invitrogen
... I provides a convenient and affordable alternativ...d with an eight-port disposable manifold, the Stat... with multi-channel pipettes. The eight-port manif...uids in volumes of 100, 200, 250, or 300mL with we...
Biology Products: